Back to Peptide Library
GLP-1 Receptor Agonist

Semaglutide

Long-Acting GLP-1 Analog • Once-Weekly Dosing

Semaglutide is a long-acting GLP-1 receptor agonist used for type 2 diabetes and chronic weight management. It reduces appetite, slows gastric emptying, improves glucose-dependent insulin release, suppresses glucagon, and has extensive human clinical-trial evidence.

Weight Loss Appetite Control Glucose Regulation Cardiometabolic
Protocol Snapshot

Semaglutide Quick Reference

Verified Vendors
Semaglutide
Semaglutide GLP-1 peptide vial illustration
Compare Verified Vendors
  • Current price and availability
  • Price per mg and vial-size comparison
  • Testing and fulfillment details
Compare
View Price Index
Starting Dose
0.25mg
Once weekly for the first four weeks.
Maintenance
1.7–2.4mg
Once weekly for weight management; 2.4mg is recommended.
Class
GLP-1 Agonist
Single-receptor incretin therapy.
Half-Life
~7 Days
Supports once-weekly injection schedules.
Peptide Grade
GradeA
STEP, SELECT, and FLOW data plus multiple approved indications give semaglutide an unusually strong evidence base; gastrointestinal intolerance and lean-mass loss during rapid weight reduction are the main practical limitations.
Research Community Safety
Foundation

Research context, mechanisms, and practical use cases

What Is Semaglutide?

Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist. It mimics GLP-1, a hormone naturally released from the small intestine after eating that helps regulate appetite, gastric emptying, insulin secretion, and glucagon release.

The molecule is engineered to resist rapid enzymatic breakdown and bind strongly to albumin, producing an approximate half-life of seven days. This supports once-weekly subcutaneous dosing.

Unlike dual- or triple-receptor agonists, semaglutide acts through the GLP-1 receptor alone. Its effects on appetite, insulin secretion, glucagon, and gastric emptying are therefore attributable to a well-characterized single incretin pathway.

Semaglutide Benefits

Semaglutide has one of the strongest clinical-evidence bases in the weight-management category, including large Phase 3 trials and cardiovascular and kidney-outcome studies.

Clinically Significant Weight Loss

In STEP-1, adults without diabetes lost an average of 14.9% of body weight at 68 weeks with 2.4mg weekly versus 2.4% with placebo.

Appetite Suppression

GLP-1 signaling in the hypothalamus and brainstem increases satiety, reduces hunger signals, and lowers the reward value of food.

Slower Gastric Emptying

Food leaves the stomach more slowly, which can increase fullness and reduce meal size, but also contributes to nausea, reflux, and gastroparesis risk.

Glucose Control

Semaglutide increases glucose-dependent insulin secretion and suppresses glucagon when blood glucose is elevated.

Cardiovascular Protection

The SELECT trial reported a 20% reduction in major cardiovascular events in adults with overweight or obesity and established cardiovascular disease.

Kidney Outcomes

The FLOW trial reported a 24% reduction in clinically important kidney outcomes in people with type 2 diabetes and chronic kidney disease.

Protocol Planning

Dosing, cycling, and preparation

Semaglutide Dosing Protocol

Semaglutide uses a slow titration schedule to reduce gastrointestinal side effects. Do not skip titration steps or increase the dose while side effects remain significant.

Weight Management

Weeks 1–4
0.25mg once weekly
Weeks 5–8
0.5mg once weekly
Weeks 9–12
1mg once weekly
Weeks 13–16
1.7mg once weekly
Week 17+
1.7mg or 2.4mg once weekly; 2.4mg is recommended
Higher Dose
Current U.S. labeling permits escalation to 7.2mg after at least four weeks at 2.4mg when additional weight reduction is clinically indicated

Type 2 Diabetes

Weeks 1–4
0.25mg once weekly
Week 5+
0.5mg once weekly
Escalation
May increase to 1mg or 2mg weekly when clinically appropriate
Timing
Same day each week, with or without food
Missed Dose
Follow the specific product prescribing instructions
Maintenance Dose Selection

For weight management, 2.4mg is the recommended maintenance dose and 1.7mg is an approved alternative. A higher 7.2mg dose is now available for selected adults after tolerating 2.4mg, but dose selection should reflect treatment response and gastrointestinal tolerance.

Semaglutide Reconstitution

5mg Vial + 2mL BAC Water

Strength
2.5mg/mL
0.25mg
10 units on a U-100 syringe
1mg
40 units on a U-100 syringe
Storage
Refrigerate after reconstitution
Reconstitution Calculator

10mg Vial + 2mL BAC Water

Strength
5mg/mL
0.25mg
5 units on a U-100 syringe
2mg
40 units on a U-100 syringe
Storage
Refrigerate after reconstitution
Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

  • Food often becomes less interesting, making calorie control feel easier and less dependent on willpower.
  • Many users report smaller portions, less snacking, and fewer cravings within the first several weeks.
  • Weight loss of approximately 8%–18% over six to twelve months is commonly reported.
  • Users who maintain resistance training and protein intake report better strength and body-composition outcomes.
  • Lower doses are sufficient for some people and may produce better adherence with fewer side effects.
  • Appetite suppression is often strongest for several days after the weekly injection.

Negative Reports

  • Nausea is most common after dose increases and may last one to two weeks at each new dose.
  • Constipation, reflux, fatigue, food aversion, and difficulty eating enough protein are frequent complaints.
  • Hair shedding and a gaunt facial appearance may occur with rapid or substantial weight loss.
Stacking & Synergy

Potential Semaglutide pairings and tracking context

Relevant Combinations

Resistance Training + Protein

The most important combination for preserving lean mass. Prioritize regular resistance training and adequate protein while appetite is suppressed.

Semaglutide + BPC-157 / TB-500

No established interaction is known, but claims that BPC-157 reduces semaglutide-related GI symptoms are anecdotal and unsupported by controlled trials.

Semaglutide + CJC-1295 / Ipamorelin

Community users pair this GH-releasing combination with Semaglutide during recomposition-focused fat-loss phases, aiming to support training performance and lean-mass retention. No controlled study has shown that the stack prevents Semaglutide-associated lean-mass loss.

Semaglutide + Tesamorelin

Tesamorelin is known for reducing visceral fat in its approved treatment setting. RUO communities pair it with Semaglutide to combine visceral-fat targeting with systemic appetite suppression, but this combination has not been validated in controlled trials.

Free with login

Track in Journal

Track Semaglutide with the markers that matter most for this compound.

  • Weekly weight and waist trend.
  • Appetite, cravings, and GI tolerance.
  • Strength, protein intake, and hydration.
Start Tracking
Common Questions

Practical Semaglutide answers

Are Ozempic and Wegovy the same compound?

Both contain semaglutide, but their approved indications, dose ranges, delivery products, and prescribing instructions differ.

Does Semaglutide need to be cycled?

Approved protocols use ongoing treatment rather than short peptide cycles. Stopping commonly allows appetite and weight regain to return.

Why is titration so slow?

Four-week dose steps give gastrointestinal effects time to settle. Escalation can be delayed when tolerability remains poor.

Can it be combined with another GLP-1 drug?

Approved semaglutide products should not be combined with another semaglutide product or another GLP-1 receptor agonist.

Safety Notes

Side effects, contraindications, and precautions

Semaglutide Side Effects

Gastrointestinal effects are common, especially during titration. Slow dose escalation and smaller meals usually improve tolerability, but serious complications can occur.

Seek medical care for severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, jaundice, signs of dehydration, severe constipation with abdominal distention, or symptoms of an allergic reaction.
In Published Research
  • Common: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, and fatigue.
  • Less common: reflux, bloating, gas, dizziness, injection-site reactions, and hair loss.
  • Important risks include gallbladder disease, clinically significant delayed gastric emptying, dehydration-related kidney injury, and possible pancreatitis.
What Users Report
  • Nausea and constipation are most frequently reported during dose escalation.
  • Fatigue, low energy, reflux, sulfur burps, and reduced ability to eat enough protein are common complaints.
  • Rapid weight loss may contribute to hair shedding, facial-volume loss, and reduced strength when nutrition and training are inadequate.

Semaglutide Contraindications and Precautions

Do Not Use If You Have

  • A personal or family history of medullary thyroid carcinoma.
  • Multiple Endocrine Neoplasia syndrome type 2.
  • Known hypersensitivity to semaglutide or product ingredients.
  • Pregnancy. Semaglutide used for weight reduction should be discontinued when pregnancy is recognized and at least two months before a planned pregnancy.

Use Caution With

  • A history of pancreatitis, gallstones, gallbladder disease, or severe gastrointestinal disease.
  • Gastroparesis or persistent delayed gastric emptying.
  • Kidney disease, especially if vomiting or diarrhea may cause dehydration.
  • Diabetic retinopathy, particularly when glucose levels may improve rapidly.
  • Upcoming surgery or anesthesia because delayed gastric emptying may increase aspiration risk.

Drug Interactions

Insulin and sulfonylureas can increase hypoglycemia risk when combined with semaglutide. Delayed gastric emptying may alter the absorption timing of oral medications. Do not combine semaglutide with another GLP-1 receptor agonist or multi-agonist containing GLP-1 activity.

Monitoring

Monitor body weight, waist measurement, gastrointestinal tolerance, hydration, glucose, HbA1c when relevant, kidney function when clinically indicated, gallbladder symptoms, and lean-mass preservation. People with diabetes should monitor for hypoglycemia when using insulin or sulfonylureas.

Regulatory Status

FDA-approved semaglutide indications include type 2 diabetes treatment, chronic weight management, cardiovascular-risk reduction, and reduction of kidney-disease progression risk in specific eligible populations. Each branded formulation has its own indication, dose range, and prescribing instructions.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

We view Semaglutide as proven and effective for appetite control and weight loss. It was one of the early game-changers in the GLP-1 space and helped a lot of people get results when options were more limited. However, newer dual and triple agonists have largely surpassed it for most users seeking maximum fat loss and body recomp. Still useful in certain cases or at lower doses, but no longer our top GLP-1 recommendation.


It’s still a solid tool if budget or access is an issue, but we personally prefer the more advanced options for better overall outcomes and fewer limitations, such as Reta or Tirz. Not bad, just no longer the best in class and the Ozempic face you've heard about online is real. No matter which GLP you are taking, you must meet your daily food intake and especially protein goals. This is a non-negotiable in our view.